Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bruker - BRKR

BRKR

Close Chg Chg %
52.48 1.98 3.77%

Closed Market

54.46

+1.98 (3.77%)

Volume: 2.17M

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: bruker - BRKR

BRKR Key Data

Open

$53.50

 Day Range

52.20 - 54.57

52 Week Range

28.53 - 64.64

 Market Cap

$8.05B

Shares Outstanding

151.94M

 Public Float

103.19M

Beta

1.17

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.16

Yield

37.73%

 Dividend

$0.05

EX-DIVIDEND DATE

Dec 8, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.90M

  

BRKR Performance

1 Week
 
 13.20%
 
1 Month
 
 20.67%
 
3 Months
 
 54.37%
 
1 Year
 
 -10.40%
 
5 Years
 
 -7.76%
 

BRKR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About bruker - BRKR

Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.

BRKR At a Glance

Bruker Corp.
40 Manning Road
Billerica, Massachusetts 01821
Phone 1-978-663-3660 Revenue 3.37B
Industry Medical Specialties Net Income 113.10M
Sector Health Technology 2024 Sales Growth 13.557%
Fiscal Year-end 12 / 2025 Employees 11,396
View SEC Filings

BRKR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 77.488
Price to Sales Ratio 2.603
Price to Book Ratio 4.992
Price to Cash Flow Ratio 34.87
Enterprise Value to EBITDA 19.268
Enterprise Value to Sales 3.226
Total Debt to Enterprise Value 0.207

BRKR Efficiency

Revenue/Employee 295,401.895
Income Per Employee 9,924.535
Receivables Turnover 4.801
Total Asset Turnover 0.669

BRKR Liquidity

Current Ratio 1.602
Quick Ratio 0.769
Cash Ratio 0.143

BRKR Profitability

Gross Margin 49.344
Operating Margin 11.282
Pretax Margin 6.146
Net Margin 3.36
Return on Assets 2.249
Return on Equity 7.162
Return on Total Capital 2.809
Return on Invested Capital 3.441

BRKR Capital Structure

Total Debt to Total Equity 126.055
Total Debt to Total Capital 55.763
Total Debt to Total Assets 38.667
Long-Term Debt to Equity 122.429
Long-Term Debt to Total Capital 54.159
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bruker - BRKR

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.42B 2.53B 2.96B 3.37B
Sales Growth
+21.66% +4.67% +17.14% +13.56%
Cost of Goods Sold (COGS) incl D&A
1.20B 1.22B 1.45B 1.71B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
89.20M 88.80M 114.90M 183.80M
Depreciation
51.80M 51.70M 67.80M 84.70M
Amortization of Intangibles
37.40M 37.10M 47.10M 99.10M
COGS Growth
+15.42% +1.59% +18.27% +17.79%
Gross Income
1.21B 1.31B 1.52B 1.66B
Gross Income Growth
+28.55% +7.72% +16.09% +9.51%
Gross Profit Margin
+50.17% +51.63% +51.17% +49.34%
2021 2022 2023 2024 5-year trend
SG&A Expense
782.00M 843.30M 1.02B 1.27B
Research & Development
220.80M 235.90M 294.80M 376.50M
Other SG&A
561.20M 607.40M 729.40M 893.80M
SGA Growth
+17.31% +7.84% +21.45% +24.03%
Other Operating Expense
2.80M 3.80M 10.30M 11.00M
Unusual Expense
14.80M 21.50M 31.80M 138.20M
EBIT after Unusual Expense
413.40M 438.00M 450.50M 241.60M
Non Operating Income/Expense
(5.50M) (8.00M) 110.10M 13.20M
Non-Operating Interest Income
900.00K 4.10M 7.50M 9.30M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
14.30M 16.10M 16.40M 47.90M
Interest Expense Growth
-0.69% +12.59% +1.86% +192.07%
Gross Interest Expense
14.30M 16.10M 16.40M 47.90M
Interest Capitalized
- - - -
-
Pretax Income
393.60M 413.90M 544.20M 206.90M
Pretax Income Growth
+74.31% +5.16% +31.48% -61.98%
Pretax Margin
+16.28% +16.36% +18.36% +6.15%
Income Tax
113.00M 116.40M 117.70M 91.40M
Income Tax - Current - Domestic
2.20M (7.90M) 4.70M 11.00M
Income Tax - Current - Foreign
118.00M 135.30M 138.70M 144.20M
Income Tax - Deferred - Domestic
(10.30M) (4.80M) (22.90M) (49.50M)
Income Tax - Deferred - Foreign
3.10M (6.20M) (2.80M) (14.30M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
280.60M 298.50M 428.50M 113.80M
Minority Interest Expense
3.50M 1.90M 1.30M 700.00K
Net Income
277.10M 296.60M 427.20M 113.10M
Net Income Growth
+75.60% +7.04% +44.03% -73.53%
Net Margin Growth
+11.46% +11.72% +14.41% +3.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
277.10M 296.60M 427.20M 113.10M
Preferred Dividends
- - - -
-
Net Income Available to Common
277.10M 296.60M 427.20M 113.10M
EPS (Basic)
1.8302 1.996 2.918 0.7591
EPS (Basic) Growth
+77.91% +9.06% +46.19% -73.99%
Basic Shares Outstanding
151.40M 148.60M 146.40M 149.00M
EPS (Diluted)
1.8123 1.9853 2.9022 0.7565
EPS (Diluted) Growth
+77.55% +9.55% +46.18% -73.93%
Diluted Shares Outstanding
152.90M 149.40M 147.20M 149.50M
EBITDA
517.40M 548.30M 597.20M 563.60M
EBITDA Growth
+45.75% +5.97% +8.92% -5.63%
EBITDA Margin
+21.40% +21.67% +20.15% +16.74%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 51.267
Number of Ratings 16 Current Quarters Estimate 0.416
FY Report Date 03 / 2026 Current Year's Estimate 2.144
Last Quarter’s Earnings 0.65 Median PE on CY Estimate N/A
Year Ago Earnings 1.879 Next Fiscal Year Estimate 2.443
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 16 13
Mean Estimate 0.42 0.41 2.14 2.44
High Estimates 0.57 0.48 2.44 2.84
Low Estimate 0.27 0.34 2.00 2.16
Coefficient of Variance 18.15 11.84 4.86 7.47

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 6
OVERWEIGHT 2 2 1
HOLD 5 5 5
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Bruker - BRKR

Date Name Shares Transaction Value
Aug 13, 2025 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 79,539 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 2,420,371.77
Aug 13, 2025 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 78,159 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 2,378,378.37
Aug 13, 2025 Gerald N. Herman EXECUTIVE VICE PRESIDENT, CFO 76,739 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.78 per share 2,362,026.42
Aug 13, 2025 Mark Robert Munch EXEC VP&PRES BRUKER NANO INC. 107,198 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 3,262,035.14
Aug 13, 2025 Mark Robert Munch EXEC VP&PRES BRUKER NANO INC. 106,091 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 3,228,349.13
Aug 13, 2025 Mark Robert Munch EXEC VP&PRES BRUKER NANO INC. 104,812 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.78 per share 3,226,113.36
Aug 13, 2025 Frank H. Laukien PRESIDENT & CEO; Director 38,455,167 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 1,170,190,731.81
Aug 13, 2025 Frank H. Laukien PRESIDENT & CEO; Director 38,450,510 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.43 per share 1,170,049,019.30
Aug 13, 2025 Frank H. Laukien PRESIDENT & CEO; Director 38,445,672 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.78 per share 1,183,357,784.16
May 20, 2025 Laura A. Francis Director 4,498 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Thomas Bures Chief Accounting Officer 3,472 Open market or private purchase of non-derivative security Non-derivative transaction at $47.4 per share 164,572.80
Feb 21, 2025 William Alderman Linton Director 48,723 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Richard A. Packer Director 84,202 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Robert J. Rosenthal Director 34,261 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Adelene Q. Perkins Director 24,624 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Hermann Fritz Requardt Director 26,445 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 John A. Ornell Director 26,445 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bruker in the News